Clinical Trials Logo

Clinical Trial Summary

This research is a multi-center prospective cohort interventional study aimed to determinate the capabilities of remote 1-minute single-lead electrocardiogram monitoring for cardiotoxicity detection, during two- three weeks (depending on the scheme of polychemotherapy) after the first cycle of polychemotherapy in patients with the first diagnosed cancer.


Clinical Trial Description

The study planned to include 130 patients and will be conducted in three stages: Stage one - screening (the day before chemotherapy treatment): 1. Signing a voluntary informed consent to participate in the study; 2. Clinical examination; Questioning: finding out the complaints. Anamnesis morbid: investigation of the history of cardiovascular diseases (the presence of hypertension, ischemic heart disease, diabetes mellitus, congenital heart disease, heart surgery in the past). Anamnesis vitae: investigation of the history of patient's life (place of birth, development in childhood and adolescence, tobacco smoking, consumption of alcohol beverage, narcotic drugs, sleeping pills and sedatives, strong tea and coffee). 3. Assessment patient's risk profile according to the cardiotoxicity risk assessment scale for treatment of tumors (C.M. Larsen assessment scale 2014). Risk level-the sum of points of all risks ((1) the risk associated with the specific chemotherapy that will be received and (2) the risk related to co-existing cardiac risk factors, age and sex of patients), these factors can be used to generate a risk score: >6 points-very high risk, 5-6 points - high risk; 3-4 points- intermediate risk; 1-2 points-rare risk; 4. All patients included in the study will be registered in single-lead ECG server base and will be trained to use single-lead electrocardiograph themselves. Before starting chemotherapy, each patient will record an 1-minute single-lead ECG. 5. Instrumental examination: transthoracic echocardiography with assessment of left ventricular ejection fraction (LVEF) and speckle-tracking global longitudinal strain (GLS), standard 12-lead electrocardiography; 6. Laboratory testing: cardiac serum biomarkers-n-terminal pro b-type natriuretic peptide(NT-proBNP), highly sensitive troponin I. Stage two - interim home control (during 2-3 weeks after first cycle of the chemotherapy): During this period, patients will registrate a single-lead electrocardiogram by themselves using single-lead ECG device, every day the patient should do at least 5 ECG records. The data will be sent to the server database, where cardiologist will check it for pathology, poor quality and will contact patients, if needed. Stage three - final control (after first course of the chemotherapy): 1. Patients' clinical examination, complaints registration; 2. Instrumental examination: transthoracic echocardiography with assessment of left ventricular ejection fraction (LVEF) and speckle-tracking global longitudinal strain (GLS), standard 12-lead electrocardiography; 3. Laboratory testing:cardiac serum biomarkers -n-terminal pro b-type natriuretic peptide (NT-proBNP), highly sensitive troponin I); 4. Evaluation of outcomes,depending on the patient's complaints, the results of instrumental and biochemical test methods carried out. The patient will be given recommendations necessary for their cardiovascular disorders correction; 5. Database compilation and statistical processing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05676606
Study type Interventional
Source I.M. Sechenov First Moscow State Medical University
Contact
Status Completed
Phase N/A
Start date December 10, 2020
Completion date May 25, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05271162 - Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines Phase 3
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Recruiting NCT04092309 - Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation N/A
Recruiting NCT04790266 - Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
Enrolling by invitation NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Not yet recruiting NCT05040867 - Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients N/A
Recruiting NCT05851053 - Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
Recruiting NCT05992337 - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Enrolling by invitation NCT04877899 - Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
Recruiting NCT05096338 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Recruiting NCT05078190 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Recruiting NCT04632407 - Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study? N/A
Completed NCT00543062 - Staccato Prochlorperazine Thorough QT/QTc Phase 1
Recruiting NCT05159479 - Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
Not yet recruiting NCT06005259 - Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX) Phase 4
Recruiting NCT05406635 - Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer N/A
Recruiting NCT04047901 - Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment N/A
Terminated NCT03038997 - Early Detection of Cardiac Toxicity in Childhood Cancer Survivors
Completed NCT01246778 - Sunitinib and Atrial Trabeculae Contractility N/A